Academia is the main source of potential assets for the future of biopharma, and as such the best sourcing partner for industry players. A link between both worlds, the venture builder model continues to grow, signalling that pharma companies and investors are willing to bring stronger, more structured support to early-stage assets. How do TTOs and venture builders work hand in hand to nurture innovation? How is this model shifting value creation and what impacts can we observe already?